Impact of insulins glulisine and aspart on postprandial glycemia after a high-glycemic index meal in children with type 1 diabetes

Katarzyna Dżygało and Agnieszka Szypowska
Department of Paediatrics, Medical University of Warsaw, Dzialdowska 1, 01-184 Warsaw, Poland

Abstract

Objective: According to current knowledge, glulisine insulin (GLU) has a slightly faster onset of action than aspart (ASP) insulin. Therefore, GLU might lead to a better postprandial profile than ASP following the consumption of high-glycemic index (H-GI) meals. The aim of this study was to assess differences in the action of GLU and ASP after the consumption of a H-GI meal in type 1 diabetic children treated with insulin pumps.

Design: Fifty-six type 1 diabetic children of mean age 14.7 ± 2.0 years were included in a randomized, double-blind, two-way crossover study. The subjects were allocated to one of two treatment orders: GLU–ASP and ASP–GLU. They were given a H-GI breakfast for two subsequent days.

Methods: The primary outcome was postprandial glycemia (PPG) based on continuous glucose monitoring system and self monitoring of blood glucose levels during 3 h of follow-up. The secondary outcomes were the frequency of hypoglycemia, glucose area under the curve, mean amplitude of glycemic excursion, and glycemic rise.

Results: There were no significant differences between the groups with regard to PPG in the determined time intervals as well as with respect to the secondary outcomes. Between 60 and 120 min after food consumption in both study groups, blood glucose levels were close to or above 10.0 mmol/l. Glucose peaks were higher in the GLU–ASP group than in the ASP–GLU group (90 min: $P = 0.065$; 120 min: $P = 0.052$). Most of the episodes of hypoglycemia were observed after the second hour of follow-up.

Conclusions: No statistically significant difference was found between GLU and ASP with regard to PPG after the consumption of a H-GI breakfast. Neither GLU nor ASP stabilized the glycemic profile after the consumption of a H-GI meal.

Introduction

The major determinant of HbA1c is postprandial glycemia (PPG). Postprandial glycemia deviations cause glucose toxicity and accelerate the progression of diabetic complications. It has been confirmed that postprandial hyperglycemia is an independent risk factor for macrovascular diseases and may occur even when overall metabolic control seems to be appropriate on the basis of HbA1c levels (1). Therefore, one of the main contributing factors of a stable glycemic profile is the reduction of postprandial glucose levels. It is particularly difficult to maintain tight glycemic control after the consumption of high-glycemic index (H-GI) meals. Due to rapid absorption, H-GI foods cause a high increase in glucose levels, with the highest peak being observed in the first
hour after meal consumption followed by a decrease in glucose levels in the second hour after consumption (2). Despite the fact that H-GI products are not recommended for people with diabetes, children prefer eating them.

Clinical studies have shown that all rapid-acting insulin analogs (aspart, lispro, and glulisine) provide better postprandial control than regular human insulin (3). However, the most recent data indicate that there might be some subtle differences between these analogs. Due to the absence of hexamer-promoting zinc, glulisine insulin (GLU) has been shown to have earlier onset of action, faster absorption, and significantly higher metabolic effect compared with lispro insulin and aspart insulins (ASP) (4, 5, 6). Considering these facts, we hypothesized that GLU should lead to a better postprandial profile than ASP after the consumption of H-GI meals. Although there are a few studies that have compared the properties of rapid-acting insulin analogs in adults (7, 8, 9, 10), the number of studies in a pediatric population is still limited (10, 11).

The objective of this study was to determine whether GLU is more effective than ASP with regard to postprandial glycemic control after the consumption of a H-GI meal in children with type 1 diabetes mellitus (T1DM) treated with continuous subcutaneous insulin infusion (CSII).

Subjects and methods
This was a prospective, randomized, double-blind, crossover controlled study conducted between September 2011 and September 2012 in the Department of Paediatrics at the Medical University of Warsaw, Poland. The study was carried out according to the guidelines of the CONSORT statement (12). The study included teenagers aged between 10 and 18 years with T1DM for at least 1 year who were treated with CSII for at least 3 months and used the same insulin analog for at least 3 months before study entry. Exclusion criteria were the following: remission phase defined as daily insulin dose <0.5 unit/kg of body mass per 24 h, concomitant dietary restrictions (e.g. celiac disease or food allergy), diabetes-related complications, and any disease judged by the investigator to affect the trial. To be randomized, the participants had to have no blood glucose fluctuations 3 h before study entry based on continuous glucose monitoring system (CGMS) values, fasting glycemia with a value between 70 and 150 mg/dl (3.9–8.3 mmol/l) on both study days, and no correction boluses for at least 3 h before test meal consumption. The study was approved by the Ethics Committee of the Medical University of Warsaw. Written consent was obtained from the caregivers and patients older than 16 years before inclusion in the study. Verbal consent was obtained from all subjects.

The subjects were randomized to two treatment schemes using a block randomization process with a block size of six, unknown to the investigator. A randomization list was generated by a computer program and kept by a staff member not involved in the study. Preparation of the study medications and refilling of insulin infusion set were controlled by nurses who were not involved in the study. In the afternoon before each study day, the whole pump site (including cartridge and catheter) and the type of insulin were changed. Only steel needle sets were used. Both the tested insulins, glulisine (Apidra; Sanofi, Paris, France) and aspart (NovoRapid; Novo Nordisk, Bagsvaerd, Denmark), are clear and colorless, so neither the patients nor the investigator were aware of the kind of insulin used. A new sensor (Sof-Sensor, Medtronic) for CGMS using the Guardian RT or Paradigm 722 system (Medtronic MiniMed, Northridge, CA, USA) was inserted in the afternoon before a 2-day study block. There is no difference between these two devices with regard to calibration algorithm. Participants who met the inclusion criteria were randomly assigned to two groups: ASP–GLU group, consisting of patients who received ASP on the first day of the trial and GLU on the second day, and GLU–ASP group, consisting of patients who received GLU on the first day of the trial and ASP on the second day.

There were 64 children included, aged 14.6 years, on average (10.3–17.9), 31 boys and 33 girls, with mean diabetes duration of 4.9 years and mean HbA1c of 8.6% (70 mmol/mol). The subjects remained hospitalized for the whole study period. HbA1c value was obtained just before study entry using HPLC, with the normal range 4.1–6.4% (21–46 mmol/mol) for subjects without diabetes. The level of HbA1c was not a limitation for the randomization. Teenagers with blood glucose fluctuations based on data from home diaries were admitted to the hospital for at least 1 week before study entry to normalize basal insulin rate and insulin-to-carbohydrate ratios (ICRs) according to the International Society for Pediatric and Adolescent Diabetes (ISPAD) recommendations. Insulin doses were calculated based on the self-monitoring of blood glucose (SMBG) nine-point profile. During hospitalization, all children were under the strict control of the diabetological team (meals were prepared by dietitians, each child had a nine-point glucose profile performed by nurses, and insulin doses were adjusted by diabetologists).
Activity was limited to sedentary activities in a research unit under comparable conditions.

The subjects were given a H-GI breakfast for two subsequent days, containing 50 g of carbohydrates (CHO) from corn flakes and 10 g from 2% fat milk. Two participants refused to eat such large portions and therefore were given a study meal containing 40 g of CHO.

The participants used their own ICR, and the dose of insulin was constant over the study period. Pre-breakfast insulin was given as a standard bolus 15 min before meal consumption. A waiting period of 15 min was included in the protocol due to the onset of action of rapid-acting insulin analogs to optimize insulin administration. Meals were consumed in the morning about 0800 h in their entirety within 15 min. The subjects were instructed not to consume any additional meal, snacks, etc. and were not given any correction boluses 3 h before each test meal and 3 h of the study period.

Capillary blood glucose levels (SMBG) were measured using Contour TS meter (Bayer HealthCare LLC) in fasted subjects before breakfast, every 30 min for the first 2 h, and finally once after 3 h of starting of the test. Additional measurements were taken if patients reported symptoms of hypoglycemia. Hypoglycemia was defined as glucose concentration below 65 mg/dl (3.3 mmol/l) with or without symptoms (13). If glycemia was lower than 65 mg/dl (3.3 mmol/l) at any time point during the first 3 h after breakfast consumption, the patients were given 10–20 g of CHO.

We expected rapid postmeal fluctuations in blood glucose values. During a rapid rate of change in glucose levels, CGMS values might be different from SMBG values because CGMS measures glucose levels in the subcutaneous tissue and not in the blood. To obtain the highest accuracy of glycemic values at a specific time point, we decided to use SMBG as a primary outcome.

The primary outcome was defined as PPG assessed 30, 60, 90, 120, and 180 min after meal bolus consumption (six-point glucose curve).

The secondary outcomes were the following: hypoglycemic episodes, mean amplitude of glycemic excursion (MAGE) and glycemic rise (GR), and glucose area under the curve (AUC).

Statistical analysis

Estimation of the sample size was based on the primary outcome (PPG). We expected to detect a difference in PPG of 30 mg/dl (1.7 mmol/l) with α = 0.05. A total of 63 participants were needed to achieve a statistical power of 80% assuming a 20% withdrawal rate. Sample size calculation was performed using StatsDirect (StatsDirect Ltd., England, UK).

Variables were analyzed on per-protocol basis, including all participants who completed the trial and complied with their allocated intervention.

Comparisons between the groups were made using Student’s t-test (unpaired, two-tailed) or, in case of nonparametric data, with the Mann–Whitney U test or Fisher’s exact test. Odds ratio (OR) was calculated with 95% CIs. Factorial ANOVA was used to assess the effect of sequence. Differences between the study groups were considered significant when P value was < 0.05.

GR (delta) was defined as the difference between maximal blood glucose (from SMBG) level during the test and basal glucose value.

AUC was estimated using the trapezoidal rule (14) – data from the CGMS. AUC was defined as the sum of absolute values of excursions from the sensor at the start and was calculated for a 3-h period following each meal and bolus combination. Incremental AUC (iAUC) was calculated by subtracting basal value from sample points below integrating AUC. Positive AUC (pAUC) was computed in two steps: estimations of intersection points of the estimated curve with baseline and integration of the area above baseline. The analysis was carried out using Statistica 10 (StatSoft, Inc., Tulsa, OK, USA) software.

Results

Of the 64 children who were randomized, 33 were assigned to the GLU–ASP study arm and 31 were assigned to the ASP–GLU arm (Fig. 1). Seven children withdrew from the study during follow-up. Finally, data of 56 (87.5%) patients were analyzed based on SMBG. The characteristics of the study subjects are given in Table 1. Data from the CGMS of three subjects were not analyzed due to problems with the sensor (loss of sensor or sensor data). The study took 2–3 days for completion. Most of the patients (91.1%) completed the study within 2 days. Five (8.9%) children needed 3 days due to impaired baseline glycemia or a correction bolus before study entry. There were different infusion site locations: abdomen (25%), upper outer thighs (15%), buttoks (25%), and arms (35%). However, we did not observe any statistical influence of site locations on blood sugar values (P > 0.05). All children, except two, consumed 60 g of CHO with mean 1.0 ± S.D. 0.24 g/kg of body weight. There were no statistically significant differences between both groups in grams of CHO per kilogram of body weight (P = 0.401).
**Postprandial glycemia**

There were no statistically significant differences with regard to the mean PPG between GLU and ASP, at each time interval (Fig. 2). Between 60 and 120 min after food consumption in both study groups, blood glucose levels were close to or above 180 mg/dl (10.0 mmol/l), and glucose peaks were higher in the GLU–ASP group than in the ASP–GLU group, but these differences were close to statistical significance (90 min: \( P = 0.065 \); 120 min: \( P = 0.052 \)) (Fig. 2).

**Hypoglycemia**

Ten (17.8%) patients treated with GLU and 11 (19.64%) patients treated with ASP suffered from hypoglycemia (<65 mg/dl, 3.3 mmol/l) (OR 0.89 (95% CI: 0.34–2.30); \( P = 0.809 \)). Most of the hypoglycemic episodes were observed after the second hour of follow-up. No severe hypoglycemia was observed.

**Glycemic excursion**

There were no differences between the groups with respect to both \( \text{IAUC} \) \( (P = 0.108) \) and \( \text{pAUC} \) \( (P = 0.158) \) (Table 2). No difference was observed between the groups with regard to MAGE, \( P = 0.309 \), and GR (delta), \( P = 0.275 \) (Table 2). No sequence or interaction effect was found.

A subanalysis in an overweight (BMI ≥ 85 and < 95 percentiles) and obese (BMI ≥ 95) population (consisting of 15 patients) revealed no statistically significant differences with regard to the mean PPG between GLU and ASP, at each time interval (Fig. 2). Between 60 and 120 min after food consumption in both study groups, blood glucose levels were close to or above 180 mg/dl (10.0 mmol/l), and glucose peaks were higher in the GLU–ASP group than in the ASP–GLU group, but these differences were close to statistical significance (90 min: \( P = 0.065 \); 120 min: \( P = 0.052 \)) (Fig. 2).
differences in PPG, MAGE, pAUC and iAUC, GR, and
episodes of hypoglycemia (P > 0.05 for all outcomes).

Discussion

To the best of our knowledge, this is the first study to
evaluate the efficacy of GLU in comparison with ASP with
respect to PPG after the consumption of H-GI foods in
type 1 diabetic children treated with insulin pumps. The
present study demonstrated similar postprandial glycemic
control of both GLU and ASP after the consumption of a
H-GI breakfast in pump users. Our findings are consistent
with results obtained by other authors (11). We did not
observe any statistical difference between both insulins
with regard to postprandial glycemic excursion during the
3-h period of follow-up. Although glucose peaks in the first
and second hour after food consumption were higher in the
GLU–ASP group than in the ASP–GLU group, these
differences were only close to statistical significance. In the
study carried out by Cemeroglu et al. (11) comparing GLU
and ASP in prepubertal type 1 diabetic children treated
with multiple daily injections, the authors demonstrated
that postprandial excursions in the second and fourth
hour were higher for GLU than for ASP.

Hypoglycemia is a common adverse effect of dosing
insulin before the consumption of H-GI foods. We did not
observe any significant differences in the incidence of
hypoglycemia between the groups. Although the inci-
dence of hypoglycemia at the 2- and 4-h postprandial time
points was similar for both GLU and ASP, an insignificant
trend toward a higher incidence of hypoglycemia was
observed in the ASP–GLU group. These findings are
consistent with those presented by Cemeroglu et al. (11).
The authors showed significantly more hypoglycemic events 2 and 4 h after H-GI food ingestion with ASP than

GLU. The results of other studies assessing the safety
and efficacy of GLU in comparison with other insulin
analogs are inconclusive; some authors have reported a
greater incidence of hypoglycemia with GLU (9), while
others have not confirmed this observation (3, 10). In a
study comparing GLU, ASP, and lispro insulin in adults
with T1DM using CSII, despite a lack of differences in the
reported incidence of hypoglycemia (≤ 70 mg/dl) per patient-year was signifi-
cantly higher for GLU than for ASP (15).

Children tend to consume H-GI meals, especially during
breakfast time. They often choose corn flakes with milk. As
shown in healthy subjects, dairy products (mainly milk)
stimulate higher insulin response despite a low GI.

Table 1

<table>
<thead>
<tr>
<th></th>
<th>GLU–ASP (n = 30)</th>
<th>ASP–GLU (n = 26)</th>
<th>ALL (n = 56)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female/male (n)</td>
<td>21/9</td>
<td>8/18</td>
<td>29/27</td>
</tr>
<tr>
<td>Age (years)</td>
<td>14.8 ± 2.1</td>
<td>14.6 ± 2.0</td>
<td>14.7 ± 2.0</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>22.6 ± 2.5 (17.1–27.3)</td>
<td>21.4 ± 3.7 (16.8–31.0)</td>
<td>22.1 ± 3.1 (16.8–31.0)</td>
</tr>
<tr>
<td>BMI percentile</td>
<td>74.3 ± 17.9 (19.0–98.0)</td>
<td>61.5 ± 27.1 (6.0–98.0)</td>
<td>68.2 ± 23.5 (6.0–98.0)</td>
</tr>
<tr>
<td>BMI SDS LMS</td>
<td>0.8 ± 0.53 (–0.89 to 2.31)</td>
<td>0.4 ± 0.97 (–1.67 to 2.36)</td>
<td>0.62 ± 0.82 (–1.67 to 2.36)</td>
</tr>
<tr>
<td>Diabetes duration (years)</td>
<td>4.4 ± 2.9</td>
<td>5.6 ± 3.2</td>
<td>5.0 ± 3.1</td>
</tr>
<tr>
<td>Pump treatment duration (years)</td>
<td>3.3 ± 2.2</td>
<td>4.3 ± 2.3</td>
<td>3.8 ± 2.3</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>8.1 ± 1.4 (6.1–11.6)</td>
<td>9.2 ± 2.2 (6.0–11.5)</td>
<td>8.6 ± 1.8 (6.0–11.6)</td>
</tr>
<tr>
<td>HbA1c (mmol/mol)</td>
<td>65.36 ± 15.2 (43.2–103.3)</td>
<td>76.88 ± 24.4 (42.1–102.2)</td>
<td>76.0 ± 20.7 (42.1–103.3)</td>
</tr>
<tr>
<td>Insulin (IU/kg)</td>
<td>0.85 ± 0.2</td>
<td>0.85 ± 0.1</td>
<td>0.85 ± 0.2</td>
</tr>
<tr>
<td>Percentage of basal insulin of total daily dose (%)</td>
<td>33.9 ± 10.2 (8.8–54.5)</td>
<td>34.9 ± 9.4 (19.7–61.1)</td>
<td>34.4 ± 9.8 (8.8–61.1)</td>
</tr>
</tbody>
</table>

BG baseline | BG 30 min | BG 60 min | BG 90 min | BG 120 min | BG 180 min

| Insulin glulisine | 112 | 131 | 177 | 197 | 180 | 125 |
| Insulin aspart   | 109 | 124 | 171 | 179 | 165 | 112 |

P value P = 0.321 P = 0.204 P = 0.433 P = 0.065 P = 0.052 P = 0.115

* BG = blood glucose (mg/dl)

Figure 2

Mean postprandial glycemia.
A potential limitation of this study was related to the fact that two subjects refused to consume 60 g of the test meal. They consumed 40 g of CHO; the glycemic index remained the same, but the glycemic load was lower. However, they were not excluded from the study due to the crossover design of the trial. We did not observe any statistical differences in grams of CHO per kilogram of body weight between the study groups. In comparison, in the study carried out by Cemeroglu et al. (11), the subjects ingested different types of products (with a similar GI) with 45, 60, or 75 g of CHO, so the glycemic load was even more unstable.

### Table 2 Secondary outcomes. Data are given as means ± s.d.

<table>
<thead>
<tr>
<th></th>
<th>GLU</th>
<th>ASP</th>
<th>P values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycemic rise (mg/dl)</td>
<td>97.5 ± 61.9</td>
<td>86.0 ± 47.9</td>
<td>0.275</td>
</tr>
<tr>
<td>(mmol/l)</td>
<td>5.41 ± 3.4</td>
<td>4.77 ± 2.6</td>
<td></td>
</tr>
<tr>
<td>pAUC (min × mg/dl)</td>
<td>7977 ± 5535</td>
<td>6704 ± 6201</td>
<td>0.108</td>
</tr>
<tr>
<td>iAUC (min × mg/dl)</td>
<td>7260 ± 881</td>
<td>6092 ± 934</td>
<td>0.158</td>
</tr>
<tr>
<td>MAGE (mg/dl)</td>
<td>67.4 ± 26.5</td>
<td>62.7 ± 21.6</td>
<td>0.309</td>
</tr>
<tr>
<td>(mmol/l)</td>
<td>3.7 ± 1.5</td>
<td>3.5 ± 1.2</td>
<td></td>
</tr>
<tr>
<td>Hypoglycemia (n(%)</td>
<td>10 (17.8%)</td>
<td>11 (19.6%)</td>
<td>0.809</td>
</tr>
</tbody>
</table>

pAUC, positive area under the curve (AUC); iAUC, incremental AUC; MAGE, mean amplitude of glycemic excursions.

Conclusions

In summary, the results of the present study indicate that GLU provides similar postprandial glycemic control as ASP after H-GI food consumption. Neither GLU nor ASP stabilized the glycemic profile after the consumption of a H-GI meal. Therefore, low-GI foods should be consumed to avoid glucose fluctuations.

### Declaration of interest

Sanofi Aventis and Novo Nordisk sponsored A Szypowska and K Dzygalo for their lectures as well as participation in medical conferences. There is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

### Funding

This study was funded by the Medical University of Warsaw, Poland.

### References


Received 22 August 2013
Revised version received 10 November 2013
Accepted 10 January 2014